Biocytogen Pharmaceuticals (Beijing) Co. Ltd

11:15 AM - 11:30 AM (PDT), Thursday, June 16, 2022
A clinical Biotech committed to becoming a global headstream of new antibody drugs with proprietary fully human antibody discovery RenMice™ platforms. Biocytogen has launched Project Integrum, the world’s first large-scale antibody discovery screening program adopting an evidence-based in vivo efficacy screening methodology to concurrently generate and screen antibodies against over 1,000 potential druggable targets, including BIC/FIC mAbs/BsAbs/BsAb-ADCs/TCRm Abs/GPCRs. Biocytogen has entered ongoing collaborations with dozens of global partners. Biocytogen’s pipeline includes 12 core products among which 2 products are in phase II multi-regional clinical trials (MRCTs) and 2 products are in phase I.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided